The panel responsible for recommending which drugs England’s National Health Service (NHS) should prescribe may recommend against the organisation using cannabis-based medical products. The National Institute for Health and Care Excellence (NICE) has issued draft guidelines which say that in many cases, medical cannabis is both too expensive to be cost-effective and not well-researched enough to be recommended.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us